Coffee the secret to a long life
Drinking coffee could help you live longer according to world-first research by heart specialists at The Alfred.
Visitor information – Everything you need to know about visiting our sites.
The Structural Heart Program commenced in 1995, when the team were pioneers in Australia, being the first to provide Transcatheter Aortic Valve Implantation (TAVI) in Victoria in 2008. TAVIs are provided to high risk patients with severe aortic stenosis. This program continues to be one of the largest in Australia.
Associate Professor Tony Walton leads a highly experienced and enthusiastic team of researchers including experienced structural heart interventional cardiologists and researchers, a structural heart fellow, doctoral (PhD) researchers and research nurses.
The Structural Heart Program research covers international commercially sponsored trials and site Investigator driven research. The research program has consistently made a significant academic contribution with international journal publications, conferences presentations and involvement in international clinical trials.
Our areas of research focus are in the assessment of new devices for the treatment of aortic and mitral valve conditions as TAVI, MitraClip and TMVR procedures, closure devices for reducing the risk of stroke such as LAA and PFO, high frequency ultrasound renal denervation studies for hypertension and assessment of new devices for the treatment of heart failure.
The Alfred TAVI program was the largest Australian site to recruit participants into the Medtronic International TAVI Clinical Trials CoreValve ANZ high risk trial, Evolut R Forward Trial and the Evolut R TAVI vs SAVR Low Risk Trial, and was a high enroller site for the Edwards Solace trial, and the Abbott Vascular Portico 1 and Portico IDE trials.
The Alfred is the only Australian site in the Medtronic SPYRAL HTN ON and OFF Meds trials for interventional treatment of hypertension with renal denervation.
We are also one of few Australian sites to be involved in the first in human trials for the transcatheter replacement of the mitral valve.
If you are interested in becoming involved with one of our clinical trials, please contact one of our helpful research team members for further information.
Head: A/Professor Antony Walton
Investigators: A/Prof Dion Stub, Dr Nay Min Htun, Dr Shane Nanayakkara and Dr Sonny Palmer
Structural heart fellow: Dr Kawa Haji
Research nurses: Rox Johnston, Bree Davidson, Tracey Shanks, Elisha Gartner, Ellen Gardner.
St Jude Medical PORTICO IDE TAVI trial
For investigation into the treatment of severe aortic stenosis with an Abbott Vascular PORTICO transcatheter aortic valve in patients who are high risk for a surgical replacement of the aortic valve
Twelve Mitral valve trial
For investigation into the treatment of severe mitral regurgitation with a Twelve Intrepid transcatheter mitral valve in patients who are high risk for a surgical replacement of the mitral valve
Medtronic SPYRAL HTN OFF Meds renal denervation trial
For investigation in the treatment of hypertension with a Medtronic SPYRAL renal denervation procedure
Closed to enrolments
Closed to enrolments
Closed to enrolments
Closed to enrolments
Completed
Completed
Completed as largest enrollers for Australasia
Drinking coffee could help you live longer according to world-first research by heart specialists at The Alfred.
COVID-19 is not a standard respiratory virus, it’s a serious threat to a number of vital organs. As medical specialists learn more about the virus and how it affects the human body, alarming complications are becoming evident including life-threatening blood clots in the lungs, heart and brain of COVID-19 patients.
Smoke from the devastating bushfires is blanketing many parts of Victoria, including Melbourne.